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Treating Macrophages with Anti-inflammatory Nanoparticles as a Strategy to 
Improve Muscle Repair 
 
Abstract 
 
The macrophage is an immune cell that is involved in host defense. More recent 
research, however, has revealed that they also play a central role in mediating the 
skeletal muscle regenerative process. Upon muscle injury, macrophages are recruited 
to the damaged site and begin differentiating into a pro-inflammatory phenotype, known 
as the M1 phenotype. M1 macrophages secrete inflammatory cytokines to facilitate the 
acute response to muscle injury, and are characterized by phagocytosis of cellular 
debris and exhibiting strong microbicidal activity. However, another hallmark of 
inflammatory macrophages is the metabolism of arginine into nitric oxide (NO), which is 
further metabolized into other reactive oxygen species such as superoxide and 
peroxynitrite. If left unchecked, prolonged macrophage inflammation leads to muscle 
cell lysis due to the persistence of reactive oxygen radicals. The capacity of 
macrophages to stimulate myogenic cells to proliferate is also reduced if inflammation 
persists. To improve muscle regeneration, we have developed and synthesized a 
nanoparticle formulation that allows controlled reduction of macrophage inflammatory 
phenotype. Previous published studies have shown lactic acid and magnesium as 
chemical agents that attenuate M1 phenotype in macrophages. We developed a poly-
lactic-co-glycolic acid (PLGA) nanoparticle emulsified with magnesium sulfate to 
attenuate the inflammatory phenotype in a murine macrophage cell line. This 
Magnesium-PLGA nanoparticle has been optimized to be uptaken by macrophages 
without affecting cell viability. We hope that these contributions make the first steps 
towards developing an injectable therapy to modulate macrophage phenotype, and can 
be used in conjunction with existing treatments to improve skeletal muscle repair 
following injury.   
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Introduction and Background 
 
Skeletal muscle injury is the most common sports-related injury, accounting for 
up to 55% of all acute sports injuries [1]. These injuries are sustained through direct 
trauma (by taking the form of lacerations, strains, and contusions) and through indirect 
trauma (related to ischemia) [2]. However, the treatment of these injuries remains as a 
challenge in primary care and sports medicine due to the debate in literature over the 
optimal treatment. PRICE (protection, rest, ice, compression, and elevation) therapy, 
stretching, and physical therapy are among the commonly used treatments for skeletal 
muscle injury [3]. We aim to develop an injectable therapy that can be used in 
conjunction with existing treatments to further improve the muscle repair process. By 
targeting macrophage-mediated inflammation in the context of muscle repair, tissue 
regeneration is improved.  
 
Stages of Skeletal Muscle Repair 
Skeletal muscle repair following injury has been classically categorized into three 
stages- the degenerative/inflammatory phase, the regenerative/anti-inflammatory 
phase, and the remodeling phase [4]. The inflammatory phase occurs within the first few 
days after muscle tissue homeostasis is disrupted. Immediately following skeletal 
muscle injury, myofibers necrotize and surrounding blood vessels rupture, forming a 
hematoma. As a result of muscle cell death, cytokine release occurs and blood-borne 
immune cells extravasate into the site of injury through the hematoma. Neutrophils are 
the first inflammatory cells to infiltrate, and they secrete cytokines TNF-α and IL-6 and 
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growth factors to create a chemoattractive environment for monocytes and 
macrophages [5]. Once macrophages arrive at the site of injury, these cytokines and 
other extracellular cues drive their inflammatory response. Infilitrating macrophages and 
monocytes become primarily responsible for directing inflammation and the transition to 
the second stage.  
The second stage, the regenerative phase, typically begins 3-5 days after injury. 
Muscle regeneration peaks at 2 weeks following injury, and slowly diminishes as it 
approaches 3-4 weeks post-injury [6]. Because muscle fibers are comprised of cells that 
are post-mitotic, injured fibers require adult muscle stem cells (MSCs) to be repaired. 
Through a complex set of regulatory mechanisms, MSCs activate and proliferate to 
generate a robust population of myoblasts that differentiate to repair injured myofibers 
and self-renew to maintain the myoblast count [7].  
The final remodeling phase completes repair following injury; connective scar 
tissue eventually forms, along with vessel and neural growth. Growth factors are heavily 
involved in facilitating this process, as transforming growth factor β1 causes significant 
fibroblast proliferation and vascular endothelial growth factor promotes angiogenesis [8].  
 
Significance of Macrophages in Muscle Repair 
Macrophages perhaps are the most important immune cell in regulating muscle 
repair, especially throughout the first two stages. Several roles have been identified as: 
phagocytosing cellular debris, directing the shift from the degenerative to regenerative 
phase through paracrine signaling, preventing muscle cell apoptosis, releasing factors 
to promote myogenic precursor cell proliferation, and secreting cytokines to facilitate 
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vascular and myofiber repair [9]. They have been well studied and have been shown to 
be absolutely necessary for adequate skeletal muscle regeneration. Multiple studies 
either depleted macrophage precursor cells or attenuated their migration and show that 
muscle regeneration following injury is dramatically impaired [10, 11, 12]. As a key 
player to the muscle healing process, macrophages are an extremely promising 
candidate to study to improve muscle repair.  
Traditionally, matured macrophages have been classified into its two distinctive 
phenotypes, the classically activated macrophage (M1) and the alternatively activated 
macrophage (M2) [13]. A resting macrophage that has not matured is typically known as 
M0. The M1 phenotype is characterized by high expression of pro-inflammatory 
cytokines such as TNF-α and IL-1β, production of reactive nitrogen and oxygen 
intermediates through the arginase pathway, and strong microbicidal activity [14]. Also 
known as inflammatory macrophages, M1 macrophages dominate at the site of injury 
for a few days following skeletal muscle trauma. In contrast, M2, or anti-inflammatory 
macrophages, primarily act 2-4 days following injury. They attenuate the inflammatory 
response by readily expressing scavenging molecules, producing ornithine and 
polyamines through the arginase pathway, and containing parasites [14]. Following the 
reduction of inflammation, M2 macrophages initiate muscle repair by encouraging MSC 
proliferation and stimulating their commitment to into myocytes [15]. Perhaps the 
greatest evidence that these phenotypes compete with each other to regulate 
inflammation is the well-studied macrophage metabolism of arginine, which can diverge 
into two pathways. M1 macrophages metabolize arginine via inducible nitric oxide 
synthase (iNOS) into nitric oxide (NO) and citrulline, whereas M2 macrophages 
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metabolize arginine via arginase into ornithine and urea [16]. This competition for limited 
arginine is a hallmark of the M1/M2 macrophage dichotomy.   
Despite the divisive features that identify the M1 and M2 phenotype, plasticity 
and flexibility also define macrophages. A macrophage that expresses M1 phenotype 
does not necessarily maintain that fate; extracellular cues can shift macrophage 
phenotype regardless of maturation status. Moreover, macrophage phenotype is 
typically not absolute M1 or M2. The phenotype is able exist in a state that falls within 
both categories of macrophages. The process of a macrophage transitioning into a 
different phenotype is known as polarization. Interestingly, polarized M1 and M2 
macrophages can have their phenotypes almost completely reversed in vitro and in vivo 
[17, 18]. At the site of muscle injury, the macrophage population consists of coexisting 
M1 and M2 phenotypes, with a higher proportion of M1 macrophages during the first 
two days after injury but a higher proportion of M2 macrophages 2-4 days post-injury as 
polarization occurs. The activation and release of M2 associated genes and cytokines 
such as IL-10 and TGF-β further cause a shift away from inflammation to produce an 
environment conducive of muscle repair. However, previous experiments have shown 
that inducing earlier shift to M2 dominance during the muscle repair process 
significantly improved tissue recovery, while delaying M2 polarization impaired tissue 
regeneration [19, 20]. This evidence is supported by the high metabolism of arginine 
into reactive nitric oxide by M1 macrophages. Nitric oxide is metabolized into other 
reactive oxygen species such as superoxide and peroxynitrite; their prolonged 
circulation in the site of muscle injury contributes to muscle cell lysis [21]. We took 
interest in these findings and investigated strategies to induce a more robust transition 
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towards an M2-polarized macrophage population within the first few days of skeletal 
muscle injury as our strategy to improve muscle repair. This began the search for a 
readily available, biocompatible chemical agent capable of targeting macrophages to 
promote M2 polarization. 
 
Selection of Chemical Factors  
 It is widely accepted that tumor-associated macrophages (TAMs) adopt a M2-like 
phenotype, but specific intra-tumoral signaling that drives these phenotype remains 
unclear. In a recent experiment, researchers used a murine model to identify lactic acid 
as a signaling molecule that induces the expression of multiple M2-associated genes in 
TAMs [22]. This finding was mirrored in another study that showed the induction of 
human-derived macrophages to M2 phenotype by tumor-derived lactic acid in vitro [23]. 
We chose lactic acid as the readily available factor that promotes M2 phenotype.  
 In addition to stimulating macrophages towards M2 phenotype, an accelerated 
reduction of M1 phenotype should help resolve inflammation. Recent research shows 
strong evidence that magnesium salts are capable of diminishing the activation of 
nuclear factor-κB (NF-κB), an inducible transcription factor responsible for regulating 
the transcription of a large number of key inflammatory genes [24]. NF-κB activation 
leads to production of inflammatory cytokines and adhesion molecules and the 
regulation of cell proliferation, apoptosis, and morphogenesis [25]. Its pro-inflammatory 
function is widely recognized and has been well studied in macrophages [26]. By 
delivering appropriate concentrations of lactic acid and magnesium to macrophages, we 
expected to be able to reduce inflammation while promoting M2 polarization. However, 
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the challenge remains to develop a method of targeting macrophages to deliver these 
soluble factors with minimal off-target effects. A biocompatible drug carrier is required 
for this purpose.   
  
 Nanoparticle Design 
 We chose to design a nano-sized particle that is stable in biological solutions. 
Nanoparticles are currently being used in medicine to improve the target efficiency of 
drugs because their size, shape, and surface properties are flexible and can be 
engineered in different ways [27.28]. Although the nanoparticle surface can be modified 
with antibodies or peptides to grant extremely specific targeting, we relied on optimizing 
the particle size and shape to target macrophages and avoid any undesired side immune 
responses. Macrophages are the primary scavengers of foreign material in the body, and 
have a higher capacity for engulfing foreign debris than other cell types. We exploited this 
characteristic of macrophages by developing spherical nanoparticles of appropriate size. 
 We used poly-lactic-co-glycolic acid (PLGA) as the polymer to develop a 
biocompatible nanoparticle suitable for our goals. PLGA, which is biologically stable yet 
biodegradable, has been used during the last two decades as one of the most attractive 
polymeric candidates for controlled drug delivery [29]. It hydrolyzes into its two 
components, lactic acid and glycolic acid, on the order of several days. The rate of 
hydrolysis increases as the pH of its environment becomes more acidic [30]. Moreover, 
PLGA can be controlled to exist in different ratios of lactic acid to glycolic acid; as this 
ratio increases, the rate of hydrolysis decreases [31]. We used PLGA at a ratio of 50% 
lactic acid to 50% glycolic acid for our nanoparticle design.  
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 The stability of PLGA in biological solutions makes it an appropriate drug carrier 
for our therapy. In general, spherical nanoparticles are formed from PLGA by dissolving 
PLGA in an organic solvent and emulsifying it in an aqueous phase, typically water. PLGA 
droplets disperse throughout the emulsion, and the emulsion is given time to allow the 
organic solvent to evaporate out of solution. This process causes the PLGA droplets to 
precipitate and harden into smaller spheres, which forms PLGA particles. The size of 
these particles is dependent on the initial PLGA concentration in the organic phase and 
the organic solvent being used [32]. We denote PLGA that has been synthesized without 
incorporating a stabilizer or other chemical agent as bare PLGA. 
 To incorporate magnesium into our PLGA nanoparticle, we used a water-in-oil-in-
water (w/o/w) double emulsion to entrap magnesium sulfate in the PLGA [33]. Particle 
size was optimized so that the macrophages would uptake them through endocytosis, 
because phagocytosis has been shown to be coupled with inflammation [34]. As the 
macrophages take up and concentrate Mg-PLGA in their endosomes, the environment 
acidifies, leading to a higher rate of hydrolysis and a higher concentration of intracellular 
lactic acid. Entrapped magnesium is also released in the cell, allowing both soluble factors 
to stimulate the cell. We hypothesize that our Mg-PLGA nanoparticles can effectively 
target macrophages to reduce inflammatory phenotype while promoting M2 polarization. 
This strategy lowers the necessary dose of magnesium sulfate and lactic acid than if 
these factors were to be injected in their soluble form. Moreover, off-target effects are 
avoided through the incorporation of a nanoparticle that is stable in biological solutions.  
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Glossary 
 Inflammatory Cytokines and Genes 
IL-6: Interleukin-6. A cytokine that is the chief stimulator of acute phase proteins, which 
respond to inflammation. A change in acute phase protein levels indicates the presence 
and intensity of inflammation [36]. However, IL-6 has been implicated to reinforce, 
although not trigger, M2 polarization in macrophages that were already being induced 
towards alternative activation [37]. 
IL-1β: Interleukin- 1β. This cytokine plays a key role in the induction of early immune 
response to inflammatory stimuli, including tissue injury. IL-1β has been shown to have 
the ability to activate the NF-κB promoter [38].  
iNOS gene: inducible Nitric Oxide Synthase. iNOS is highly expressed in inflammatory 
macrophages. The enzyme is responsible for the production of nitric oxide by catalyzing 
the metabolism of arginine. LPS and IFN-γ heavily induce iNOS expression [39].  
TNF-α: Tumor necrosis factor-α. A cytokine that is a “master regulator” of inflammatory 
cytokine production and orchestrates inflammatory cascades. Macrophages are the 
primary producers of TNF-α and are highly responsive to TNF-α [35]. 
 
 Anti-inflammatory Cytokines and Genes 
Arg1 gene: Arginase isoform 1. Arg1 competes with iNOS for arginine; Arg1 metabolizes 
arginine into ornithine and and urea. Arg1 is classically known as a M2 macrophage 
marker [40].  
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IL-10: Interleukin-10. An important anti-inflammatory cytokine that inhibits expression of 
TNF-α and IL-6 in macrophages [41]. IL-10 has been demonstrated to reduce 
inflammation in animal models of sepsis [42]. 
  
Macrophage Activation 
IFN-γ: Interferon-γ. Major M1 stimuli that has been widely used for macrophage 
polarization. IFN-γ activates macrophages through the signal transducer and activator of 
transcription 1 (STAT1) signaling pathway [43]. 
LPS: Lipopolysaccharide. An M1 stimulus that activates macrophages through the toll-
like receptor (TLR) signaling pathway [43].  Found on the surface of gram-negative 
bacteria.  
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Methods 
 Murine model cell line 
RAW 264.7 macrophages, an Abelson leukemia virus transformed cell line, were used 
throughout the experiments as a model of murine macrophages. Cells were cultured in 
high glucose DMEM supplemented with 10% heat-inactivated FBS, 1% 
penicillin/streptomycin, and 1% sodium pyruvate, and incubated at 37°C with 5% CO2. To 
maintain the cell line, cells were passaged after reaching 80% confluence, detached with 
cell scraper and 1-2 million cells were re-cultivated in T-75 flasks. Cells were typically 
cultured in this fashion until passage no. 25.  
 
3T3 murine fibroblasts were cultured as to model a connective tissue cell line in flow 
cytometry experiments. To maintain cell line, cells were cultured in high glucose DMEM 
supplemented with 10% FBS, 1% pencillin/streptomycin, and 1% sodium pyruvate, and 
incubated at 37°C with 5% CO2. Cells were passaged after reaching about 80% 
confluence, detached with trypsin, and re-cultivated in a 1:10 ratio in T-75 flasks.  
Macrophage stimulation 
In all experiments, macrophages were stimulated either with 100 ng/mL LPS or 20 ng/mL 
IFN-γ to generate an inflammatory M1 phenotype. M1 stimulants were introduced to 
macrophages at the same time as any other chemical factor being studied (lactate, 
MgSO4, Mg-PLGA).   
 Real time PCR 
300,000 cells/well were cultured onto a 6-well plate (9.5 cm2 growth area) and allowed to 
adhere overnight. Cells were then stimulated with treatment for 24h. RNA was isolated 
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using the Qiagen© RNeasy Mini Kit (Cat. No. 74104), and the High-Capacity RNA-to-
cDNATM Kit (Cat. No. 4387406) from Applied BiosystemsTM was used for reverse 
transcription. Quantitative RT-PCR was performed using SYBRTM Green Master Mix from 
Applied Biosystems (Cat. No. 4309155) and qPCR system. Data was analyzed using the 
comparative CT method [44]. HPRT was used as an appropriate housekeeping gene.  
 Griess and MTS assay 
30,000 cells/well were cultured onto a 48-well plate (0.95 cm2 growth area) and allowed 
to adhere overnight. Cells were then stimulated with treatment for 24h. Supernatant was 
collected, and samples were centrifuged at 20,000 g to remove excess nanoparticles. 
Griess reagents were used to indirectly determine the concentration of NO [45]. Through 
this two-step diazotization reaction, colorimetric determination of NO concentration is 
carried out by measuring the absorbance at 540 nm on microplate photometer. Raw 
absorbance values were converted to NO concentrations through a standard. To account 
for differences in cell viability between groups, MTS assay was performed on the cells 
after supernatant was removed [46]. MTS reagent, tetrazolium, is enzymatically reduced 
in metabolically active cells to generate a colored formazan product. The product absorbs 
light strongly at 490 nm, and the absorbance intensity is measured to quantify relative 
metabolic activity. 2 hours of incubation was allowed for MTS treatment to ensure that the 
reagent had not been completely metabolized. Absorbance values obtained from MTS 
were used to normalize NO concentration to cell viability. 
 Nanoparticle synthesis 
Magnesium was entrapped into PLGA nanoparticles using a double emulsion protocol 
[33]. Dichloromethane (DCM) was used as the organic solvent. 50 µL of saturated MgSO4 
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solution at room temperature was added into 50 mg of dissolved PLGA in DCM to form 
the initial emulsion. Poly-vinyl alcohol (PVA) was used as the stabilizing agent. Because 
the concentration of stabilizing agent used in the vortexing emulsification step primarily 
controls the size of the nanoparticles that form, 5% PVA was used in this step to create 
nanoparticles of appropriate size [33]. Nanoparticles were decanted into a stirring solution 
of 45 mLs of 0.3% PVA and left for 3 hours for DCM to evaporate and nanoparticles to 
harden. Nanoparticles were centrifuged at 20,000 g and resuspended in water to remove 
soluble magnesium and residual PVA. 
 Fluorescent nanoparticle synthesis 
Fluorescent PLGA nanoparticles were synthesized for flow cytometry and confocal 
images. DiI, an indocarbocyanine dye, was incorporated into PLGA nanoparticles for flow 
cytometry while DiO, an oxacarbocyanine dye, was incorporated into PLGA nanoparticles 
for the confocal images. For synthesis of fluorescent nanoparticles, the dye was dissolved 
with PLGA and 1% w/v F-127 Pluronic into the organic phase, and then emulsified with 
5% PVA. Fluorescent PLGA nanoparticle synthesis matched magnesium PLGA 
nanoparticle synthesis otherwise to serve as a detectable representation.  
 Flow cytometry 
RAW and 3T3 cells were co-cultured into 6-well plates at 300,000 total cells/well, and 
150,000 cells of each respective cell type. High glucose DMEM supplemented with 10% 
heat-inactivated FBS, 1% penicillin/streptomycin, and 1% sodium pyruvate was used as 
appropriate media for both cell types. Cells were allowed to adhere overnight, and 
treatment was given the following day either for 3h or 24h. Following treatment, were 
stained with APC-Cy7 anti-mouse F4/80 antibody, which is a commonly used antibody as 
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a macrophage marker. Cells in the 3h treatment groups were fixed with 2% 
paraformaldehyde so that flow cytometry could be performed on both the 3h and 24h 
timepoints concurrently. 
 TEM 
Nanoparticles were immobilized on plasma-treated carbon grid, and residual solution was 
removed with blotting paper. They were then negative-stained with uranyl acetate to 
improve contrast, and were imaged on a FEI Tecnai Transmission Electron Microscope. 
 Dynamic Light Scattering (DLS) and Zeta 
A Zetasizer instrument was used to perform DLS and Zeta measurements on 
nanoparticles. Nanoparticles were first washed to remove any excess PVA, which could 
interfere with light scattering. Following resuspension, nanoparticles were diluted 1:40 in 
water in disposable cuvettes for DLS. For Zeta, the same diluted particles were placed in 
capillary cells for measurement.  
 Confocal images  
To prepare for images, fluorescent PLGA nanoparticles were synthesized with DiO, a dye 
in the same family of dyes as DiI. After treating cells with nanoparticles for 5h, cells were 
rinsed with PBS and fixed with 2% paraformaldehyde. After thoroughly rinsing off 
paraformaldehyde, 1 µg/mL DAPI in PBS was added to cells for 5 minutes to allow the 
dye to bind to DNA for nuclear visualization. After a final rinse with PBS, samples were 
stored in 4°C overnight and imaged the next day. For imaging, samples were mounted 
onto a glass cover slip.  
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Results and Discussion 
To assess the 
potency of lactic acid to 
polarize macrophages 
towards M2 phenotype, 
we performed Griess 
assay on duplicate 
groups of RAW 
macrophages and 
normalized to MTS 
values as an indirect 
measure of NOS activity. 12.5 mM lactate was selected as an appropriate, non-toxic 
concentration after testing multiple concentrations. Macrophages stimulated with LPS 
only were representative of M1 macrophages. Figure 1 shows 25% reduction of [NO] 
output of M1 macrophages stimulated with lactate as compared to M1 macrophages. Data 
may also suggest that lactate is not extremely effective as a regulator of the TLR-
mediated signaling pathway of classical activation, which is stimulated by the presence 
of LPS in macrophages [43]. Moreover, lactate may have more potency to regulate NOS 
transcription, rather than translation (Figure 2).   
 
 
Figure 1. Lactate slightly reduces nitric oxide output in RAW 
macrophages, indicative of a reduction in NOS activity. Cells were 
treated for 24h. Following treatment, MTS reagent was introduced 
to cells and allowed to be metabolized for 2h. 
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The effects of lactate on influencing the expression of key M1 genes was 
investigated by performing RT-PCR on duplicate groups of RAW macrophages stimulated 
with or without IFN-γ. Cells were stimulated with IFN-γ to identify whether or not a different 
signaling pathway from TLR is more regulated by lactate. 10-fold reduction of iNOS 
expression upon addition of lactate suggests that lactate plays a more significant role in 
regulating the STAT1 pathway to inhibit the expression of a primary M1-associated gene. 
However, the promotion of M2 phenotype was not as prominent. While Arg1 upregulation 
Figure 2. RAW macrophage mRNA 
levels of IL-10 and Arg1 upon lactate 
treatment show contradicting 
downregulation and upregulation of 
M2-associated genes (B) (C). 
However, lactate treatment was able to 
significantly reduce iNOS expression 
(A)s. Cells were treated for 24h before 
RNA was isolated. 
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is significant and is consistent with the downregulation of iNOS expression, an 
approximate 4-fold reduction of IL-10 expression contradicts the promotion of M2 
phenotype (Figure 2). This data completes our analysis of soluble lactate as a chemical 
factor. Lactate is highly promising in reducing NOS levels in macrophages, but we were 
not able to replicate results that show a conclusive M2-promoting effect.  
 
 
 
 
 
 Preliminary testing of different Mg salts on nitric oxide output was performed. 
RAW macrophages treated with either MgSO4 or MgCl2 upon LPS stimulation showed 
to respond more to MgSO4 treatment, as shown by Griess assay in Figure 3. Both 
magnesium salts are highly soluble. Only absorbance values of samples were recorded 
to compare relative absorbance intensities between groups, rather than using standard 
to obtain nitric oxide concentrations. CaCl2 was an appropriate control to ensure that the 
divalent salt itself did not change nitric oxide output. Different concentrations were 
tested to determine dosage, and all three concentrations showed little to no cell toxicity. 
Figure 3. MgSO4 decreases absorbance intensity of Griess reaction in RAWs, 
while other salts are not capable of doing so. Cells were treated for 24h.  
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MgSO4 had much higher potency to reduce nitric oxide output than MgCl2 did, showing 
that MgSO4 should be used as the salt to deliver magnesium to macrophages.  
 M1 macrophages were treated with MgSO4 to reassess the extent to which 
magnesium can reduce nitric oxide output. Griess assay was performed on duplicate 
groups. (Figure 4) shows significant reduction of [NO] upon addition of MgSO4, with 
more reduction as the Mg concentration increases. MgSO4 potently reduced nitric 
oxide, as nitric oxide output of M1 macrophages treated with MgSO4 matched that of 
macrophages that did not receive LPS treatment.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Significant reduction of NOS activity in RAW macrophages upon 
MgSO4 treatment for 24h. At the 20 mM concentration, nitric oxide output 
matched that of non-activated macrophages.  
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A set of inflammatory genes was selected to determine the efficacy of MgSO4 in 
reducing M1 phenotype in RAWs. RT-PCR was performed on duplicate groups of cells. 
Figure 5 shows comprehensive reduction of M1 gene expression upon addition of 
MgSO4. The similar levels of iNOS expression in M0 macrophages and M1 
macrophages treated with MgSO4 match the similar levels of NO output shown 
previously in the Griess Assay. To be able to collectively reduce iNOS, TNF-α, and IL-6 
expression without being cytotoxic makes MgSO4 a highly promising agent for 
Figure 5. RT-PCR performed on RAWs reveal 
significant reduction across a panel of key 
inflammatory genes upon treatment with 
MgSO4 (A) (B) (C). Cells were treated for 24h.  
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attenuating inflammation. The motivating data shown from the experiments involving 
magnesium suggest that LPS is an appropriate M1 stimulant to use for following 
experiments. We then began formation of nanoparticles to co-deliver lactate and 
magnesium to macrophages.  
  PLGA nanoparticles are often formed by introducing PLGA dissolved in organic 
solvent into a larger volume of aqueous solution, forming PLGA droplets. As organic 
solvent evaporates, the PLGA nanoparticles precipitate into a hardened particle. 
Without adding any other chemical agents or stabilizers, this process of precipitation 
creates bare PLGA nanoparticles. The organic solvent being used can be adjusted to 
control particle size. For our bare PLGA nanoparticle formation, we used acetone as the 
organic phase and water as the aqueous phase. The nanoparticles generated were 
about 130-170 nm in diameter, as measured through detection of Brownian motion by 
the Zetasizer instrument. This size is comfortably smaller than the micron scale, which 
is typically associated with macrophage phagocytosis [47].  
 To incorporate magnesium into PLGA nanoparticles, a w/o/w double emulsion 
method was used. Saturated MgSO4 solution was emulsified into dissolved PLGA in 
dichloromethane, which was then emulsified with either 0.3% or 5% PVA. Resulting 
nanoparticles were characterized with Zeta, DLS, and TEM. Figure 6A shows that 
nanoparticles synthesized via the double emulsion protocol consistently had zeta 
potentials less negative than that of bare PLGA, suggesting that PVA is coating the 
surface of the nanoparticles and reducing the availability of negatively charged groups 
in PLGA to interact with surrounding solution. This observation was indicative that PVA 
is likely not entrapped in the PLGA, which is instead permeated with magnesium.  
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 The concentration of PVA used to 
create the second emulsion heavily influences 
the resulting size of nanoparticles; as this 
concentration increases, nanoparticle size 
decreases. The viscosity of the PVA solution 
determines the shear force applied to the 
nanoparticles during vortexing. It was reported 
that PLGA dissolved in dichloromethane 
emulsified into 5% PVA generated 140 nm 
diameter nanoparticles [33]. We confirmed 
this finding by using DLS to measure 
hydrodynamic diameter of our double 
emulsion particles synthesized with 5% PVA. 
Figure 6B shows that these nanoparticles 
had a diameter of approximately 150 ± 20 
nm. NaCl PLGA double emulsion particles 
were synthesized with the same double 
emulsion protocol. We dissolved NaCl in 
water at a concentration that matched the 
concentration of the saturated MgSO4, and 
dissolved PLGA.  
The size of these 5% PVA nanoparticles was nearly identical to the size of the 
bare PLGA, suggesting that any coating of the surface of the nanoparticles by PVA is 
Figure 6. Zeta potential of double emulsion 
particles show coating of nanoparticle 
surface by PVA (A). Double emulsion 
particles synthesized with 5% PVA match 
the size of bare PLGA, while 0.3% PVA 
double emulsion particles are much larger 
and more polydispersed. 
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not extremely significant. This thin coating was appropriate, as the small particle size 
was maintained to avoid triggering phagocytic cell mechanisms. In contrast, the 
nanoparticles synthesized with only 0.3% PVA began approaching micron size, and had 
rather high polydispersity. Figure 7 and 8 confirm the size differences between 5% and 
0.3% PVA synthesized nanoparticles.  
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Figure 7. TEM image of Mg PLGA double emulsion nanoparticles synthesized with 0.3% 
PVA during vortexing step. Scale bar = 200 nm.  
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Figure 8. TEM image of Mg-PLGA nanoparticles synthesized with 5% PVA during vortexing 
step. Scale bar = 200 nm. 
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Figure 9. Confocal image of non-activated RAWs treated with DiO PLGA 
nanoparticles for 5h. Cell nuclei were stained with DAPI. Nanoparticles are shown 
concentrated outside cell nuclei. Image analyzed with ImageJ. 
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Figure 10. Confocal image of activated RAWs treated with DiO PLGA nanoparticles 
for 5h. Cell nuclei were stained with DAPI. Nanoparticles are shown concentrated 
outside cell nuclei. Image analyzed with ImageJ. 
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DiI fluorescent nanoparticles were synthesized for analysis in flow cytometry. 
0.05% w/v DiI was added to dissolved PLGA and F-127 Pluronic in DCM, and then 
emulsified with 5% PVA to generate nanoparticles that mimic previously generated Mg 
PLGA nanoparticles. To assess the stability of DiI fluorescent PLGA nanoparticles, a 
fluorescence-over-time experiment was performed. After nanoparticles were washed, 
they were resuspended in 1% BSA in PBS, representative of cell media. Duplicates of 
three groups were tested. The 0h group was immediately centrifuged to pellet. Tubes 
were placed in 4°C for storage. The 4h and 24h groups were incubated at 37°C, spun 
down to separate the entrapped DiI and the released DiI in the supernatant, and 
fluorescence was measured on microplate spectrophotometer. Figure 11 shows that 
there was no observable reduction in fluorescence in the resuspended pellet. Evidence 
suggests that DiI is stably maintained within the nanoparticle, and that fluorescence 
detected during flow cytometry is a result of the detection of fluorescence within the 
nanoparticle. To understand the localization of the nanoparticles within the cell, Figure 
9 and 10 show that nanoparticles are highly concentrated throughout non-nuclear 
contents of the cell, presumably in the cytoplasm and in the endocytic pathway.  
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Flow cytometry was performed to show preferential uptake of nanoparticles by 
macrophages. RAWs were co-cultured with 3T3s in a 1:1 ratio and treated either with Mg 
PLGA nanoparticles (NPs) or DiI NPs. Cells were also either treated with or without LPS. 
One plate of cells was stimulated with LPS and NP treatment for 3h, while the other plate 
was stimulated for 24h. Mg-containing, DiI-negative NPs were included as a treatment to 
control for any auto-fluorescence of the nanoparticles. Gates were set along F4/80 and 
DiI fluorescence intensities so that cell populations and positive/negative nanoparticle 
fluorescence could be distinguished. F4/80+ cells were indicative of RAWs, while F4/80- 
cells were indicative of 3T3 cell population.  
  
Figure 11. DiI PLGA nanoparticles are stable in cell 
media-like solution. Nanoparticles were washed and 
suspended in 1% BSA in PBS, then incubated at 37°C for 
0h, 4h, and 24h timepoints. 
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Figure 12. MFI histograms show greater uptake of nanoparticles in RAWs than 3T3s across both timepoints, 
with differences in uptake greater at 24h (C) (D). RAWs and 3T3s were co-cultured in 6-well plates, 
stimulated for either 3h or 24h with treatment, and stained with F4/80 APC-Cy7. Flow cytometry was 
performed with lasers for PE and APC-Cy7 for detection of fluorescence from nanoparticles and F4/80. 
F4/80+ cells were gated to represent the RAW cell population, and F4/80- cells were represented as 3T3s. To 
gate for PE, cells stained with F4/80 APC-Cy7 but treated with non-fluorescent particles were also analyzed 
by flow cytometry. Gates were drawn approximately around the PE signal for this group. MFI were obtained 
from analyzing data via FlowJo. 
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Median fluorescence intensities (MFI) were plotted from dot plots. Figure 12 
shows higher relative uptake of nanoparticles in RAWs than 3T3s at both time points 
and with or without LPS. Negligible auto-fluorescence of the nanoparticles was 
observed. The histograms are plotted on the log scale; RAWs typically had twice the 
fluorescence intensity of 3T3s. More pronounced differences in MFI between cell types 
exist at 24h, suggesting that preferential uptake of nanoparticles by macrophages is 
maintained throughout at least a 24h time period (Table 2). Differences in MFI between 
cell types is also higher in LPS treated groups vs. non-LPS treated groups (Table 1 and 
2). Evidence supports that M1 macrophages can be preferentially targeted by our 
nanoparticles.  
Treatment Cell type MFI  MFIRAW/MFI3T3 
3h M0 + Mg NPs 3T3 + RAW 155 -- 
3h M0 + DiI NPs 3T3 6133 -- 
3h M0 + DiI NPs RAW 12438 2.028 
3h LPS + DiI NPs 3T3 3246 -- 
3h LPS + DiI NPs RAW 7414 2.284 
Treatment Cell type MFI MFIRAW/MFI3T3 
24h M0 + Mg NPs 3T3 + RAW 125 -- 
24h M0 + DiI NPs 3T3 2065 -- 
24h M0 + DiI NPs RAW 5731 2.775 
24h LPS + DiI NPs 3T3 2000 -- 
24h LPS + DiI NPs RAW 7054 3.527 
Table 2. MFI is greater in RAWs than 3T3s by at least a factor of 2 in both M0 and M1 cells. MFI 
difference between RAW and 3T3 is measurably greater among LPS treated cells vs. non-LPS treated 
cells at 24h.  
Table 1. MFI is greater in RAWs than 3T3s by at least a factor of 2 in both M0 and M1 cells. MFI 
difference between RAW and 3T3 is slightly greater among LPS treated cells vs. non-LPS treated 
cells at 3h.  
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The Mg PLGA nanoparticles we 
synthesized were given to cells at a 
biocompatible concentration, and RT-
PCR was performed. iNOS and IL-1β were significantly reduced in activated 
macrophages treated with Mg-PLGA compared to activated macrophages without the 
nanoparticles, but TNF-α levels remained relatively unchanged (Figure 13B). The iNOS 
knockdown showed that our nanoparticles were capable of reducing the expression of 
the primary gene that we know to induce muscle lysis during regeneration. IL-1β 
knockdown further supports the capability of the nanoparticles to reduce M1 gene 
Figure 13. iNOS and IL-1β gene expression is 
significantly reduced when cells are treated with 
Mg-PLGA nanoparticles (A) (C). The ability of the 
nanoparticles to suppress M1 phenotype is 
somewhat confounded by the fixed levels of TNF-
α (B). This may suggest the need to load higher 
amounts of magnesium into the particles.  
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expression. However, TNF-α remains as a key player in regulating the inflammatory 
response, and was not reduced in expression. Loading more magnesium into the 
nanoparticles should be explored, as TNF-α expression was highly reduced in the RT-
PCR data for cells treated with MgSO4 (Figure 5B). By delivering a higher concentration 
of magnesium to macrophages through the nanoparticles, M1 phenotype may be further 
reduced. Lactic acid seems to have played less of a role in mediating the changes in 
gene expression: RAWs treated with nanoparticles loaded with NaCl did not significantly 
reduce gene expression in any of the three major M1 genes (Figure 13). The 
concentration of lactate in the cell due to hydrolysis of PLGA may not be high enough to 
stimulate changes in gene expression, at least in the course of this 24h experiment. The 
time scales of a 24h experiment does not match the time scale of PLGA degradation, 
which is on the order of days [29]. Nevertheless, PLGA presents itself as an extremely 
promising candidate as a carrier for delivering drugs to macrophages.  
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Conclusion and Future Studies 
 
Macrophage phenotype can be exploited to resolve inflammation in the context of 
muscle repair to improve tissue regeneration. We were able to successfully synthesize 
PLGA nanoparticles with entrapped magnesium and deliver them to macrophages to 
reduce M1 phenotype. This inexpensive, stable nanoparticle formulation reduced the 
expression of key M1 genes, such as iNOS and IL-1β. Results were telling that 
magnesium played more of a role in reducing this phenotype than lactic acid, but PLGA 
was able to act as a stable carrier for drug delivery. PLGA nanoparticles were shown to 
be preferentially taken up by macrophages, suggesting that the effects of introducing 
this nanoparticle to other cell types in the body is limited upon injection. Future work 
involves treating human cell lines with the nanoparticles and translating nanoparticle 
treatment experiments in vivo. Targeting strategies to increase specificity for 
macrophages should also be studied. In vivo experiments would involve inducing 
skeletal muscle injury in mice, such as ischemia-reperfusion injury, and injecting 
nanoparticles at the site of injury. Histological analysis of muscle repair would be 
studied as an output of success. 
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